<sup>18</sup>F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab

<sup>18</sup>F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab

Dostarlimab is an immune checkpoint inhibitor (ICI) targeting the Programmed-Death-1 (PD-1) co-receptor, recently approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) as a novel therapy for recurrent or advanced endometrial cancer. We report the case of a 64-yea...

Full description

Bibliographic Details
Main Authors: Romain-David Seban, Anne Donnadieu, Gabrielle Journo, Francois-Clement Bidard, Capucine Richard, Roman Rouzier, Laurence Champion
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Diagnostics
Subjects:
<sup>18</sup>F-FDG PET/CT
endometrial adenocarcinoma
dostarlimab
immunotherapy
tumor response
microsatellite instability high/hypermutated
Online Access:https://www.mdpi.com/2075-4418/11/8/1353

Internet

https://www.mdpi.com/2075-4418/11/8/1353

Similar Items